These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37372326)

  • 1. Potential Prognostic Value of GATA4 Depends on the p53 Expression in Primary Glioblastoma Patients.
    Trąbska-Kluch B; Braun M; Orzechowska M; Paszek S; Zuchowska A; Sołek J; Kluska A; Fijuth J; Jesionek-Kupnicka D; Zawlik I
    Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA4 and DcR1 methylation in glioblastomas.
    Vaitkienė P; Skiriutė D; Skauminas K; Tamašauskas A
    Diagn Pathol; 2013 Jan; 8():7. PubMed ID: 23320456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
    Agnihotri S; Wolf A; Munoz DM; Smith CJ; Gajadhar A; Restrepo A; Clarke ID; Fuller GN; Kesari S; Dirks PB; McGlade CJ; Stanford WL; Aldape K; Mischel PS; Hawkins C; Guha A
    J Exp Med; 2011 Apr; 208(4):689-702. PubMed ID: 21464220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
    Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
    Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.
    Jesionek-Kupnicka D; Szybka M; Malachowska B; Fendler W; Potemski P; Piaskowski S; Jaskolski D; Papierz W; Skowronski W; Och W; Kordek R; Zawlik I
    DNA Cell Biol; 2014 Apr; 33(4):217-26. PubMed ID: 24506545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
    Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
    J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium.
    Chmelarova M; Kos S; Dvorakova E; Spacek J; Laco J; Ruszova E; Hrochova K; Palicka V
    Clin Chem Lab Med; 2014 Aug; 52(8):1229-34. PubMed ID: 24651021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    Kurdi M; Butt NS; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Dallol A; Mohamed F; Bari MO; Samkari A; Lary AI; Alkhayyat S
    J Neurooncol; 2021 May; 152(3):541-549. PubMed ID: 33661424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
    Watanabe T; Katayama Y; Komine C; Yoshino A; Ogino A; Ohta T; Fukushima T
    Int J Cancer; 2005 Feb; 113(4):581-7. PubMed ID: 15455376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
    J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer.
    Casarotto M; Lupato V; Giurato G; Guerrieri R; Sulfaro S; Salvati A; D'Angelo E; Furlan C; Menegaldo A; Baboci L; Montico B; Turturici I; Dolcetti R; Romeo S; Baggio V; Corrado S; Businello G; Guido M; Weisz A; Giacomarra V; Franchin G; Steffan A; Sigalotti L; Vaccher E; Boscolo-Rizzo P; Jerry P; Fanetti G; Fratta E
    Clin Epigenetics; 2022 Dec; 14(1):171. PubMed ID: 36503584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.